BioCentury
ARTICLE | Clinical News

Alzheon planning AD Phase III

March 12, 2016 1:47 AM UTC

Alzheon Inc. (Framingham, Mass.) said it plans to start Phase III testing of ALZ-801 "in the near future" to treat mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4). ALZ-801 is an oral small molecule prodrug of tramiprosate, an inhibitor of amyloid formation and neurotoxicity.

Last year, Alzheon said tramiprosate improved cognition in patients homozygous for APOE4 in a subgroup analysis of two earlier Phase III studies that showed lack of efficacy in the total AD patient population. At the time, Alzheon said the analysis supported advancing ALZ-801 in homozygous APOE4 patients (see BioCentury Extra, Nov. 6, 2015). ...